Collin Todd
Senior Vice President of Strategy & Business DevelopmentMr. Collin Todd is Senior Vice President of Strategy & Business Development of Odyssey Therapeutics, Inc. from June 2024. Since joining Odyssey in December 2021, Mr. Todd has overseen Series B and Series C financings and the execution of collaboration agreements, including those with J&J and Pfizer. Mr. Todd has over a decade of experience in investing, company operations, corporate and business development and strategic planning in the biotechnology industry. From September 2017 to December 2021, Mr. Todd served in various strategy and business development roles at SpringWorks Therapeutics, Inc. Prior to SpringWorks, Mr. Todd was a strategy professional at Moderna, Inc. Mr. Collin Todd is Director of CTRL Therapeutics USA, Inc. Mr. Todd was an Analyst on the Private Equity team at OrbiMed Advisors, L.L.C. Prior to joining OrbiMed, Mr. Todd was an investment banking analyst in the healthcare group at Bank of America Merrill Lynch where he focused on mergers and acquisitions, financing and strategic advisory for biotech and pharma clients in the US and EU. Mr. Todd holds a B.A. in Economics from the University of California, Los Angeles.
Positions
- Company NameOdyssey Therapeutics, Inc.Stock CodeODTXPositionSenior Vice President of Strategy & Business DevelopmentColleagues
- GDGary D. GlickFounder, President, CEO & Director
- JMJeffrey Marc LeidenIndependent Chairman of the Board
- JHJason HaasChief Financial Officer
- ELEicke LatzScientific Co-Founder
- KLKim LewisScientific Co-Founder
- SCStephen C. BlacklowChairman of Scientific Advisory Board
- IFIan F. SmithIndependent Director
- VOValerie OdegardIndependent Director
